The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers

Authors
Category Primary study
JournalJournal of Hepatology
Year 2023
This article has no abstract
Epistemonikos ID: 14aea1f4d62e73a13afa37176ebc68f2cccba40d
First added on: Feb 16, 2025